Diagnostic and prognostic value of fibroblast growth factor 23 in acute kidney injury: systematic review and meta-analysis.
Xiaohang Pei, Hang Gao, Lina Zhang
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the diagnostic and prognostic value of fibroblast growth factor 23 (FGF23) in acute kidney injury (AKI). Analyzing 23 studies, the pooled sensitivity for AKI diagnosis was 0.79 and specificity was 0.82, with an area under the summary receiver operating characteristic curve (SROC AUC) of 0.87. FGF23 may serve as a complementary biomarker for risk stratification in AKI.
Key findings
- Pooled sensitivity for AKI diagnosis was 0.79 (95% CI 0.73-0.86) and specificity was 0.82 (95% CI 0.75-0.89).
- The area under the summary receiver operating characteristic curve (SROC AUC) for AKI diagnosis was 0.87 (95% CI 0.81-0.92).
- For AKI mortality, pooled sensitivity was 0.77 (95% CI 0.69-0.84) and specificity was 0.76 (95% CI 0.70-0.82).
- iFGF23 demonstrated higher diagnostic accuracy than cFGF23, with AUCs of 0.91 vs 0.81.
Why it matters
FGF23 may enhance the diagnostic and prognostic assessment of acute kidney injury, providing clinicians with a potential tool for better risk stratification and management of affected patients.
What to keep in mind
Substantial heterogeneity was observed in the results, which may limit the interpretation of the findings.